FDA approval of VEPPANU is a major catalyst validating the PROTAC platform and providing a new revenue stream. Monitor for the announced third-party commercialization partner and initial sales figures post-launch. Given ARVN's low market cap (~$633M), upside potential is significant, but historical stock performance after positive news has been poor; consider profit-taking on initial pop if sustained.
ARVN drugs
ARVN drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 1 $10.51entry
- T+1 · 7mo ago +2.57%α +2.91% · $10.78
- T+5 · 6mo ago −3.04%α −5.39% · $10.19
- T+20 · 6mo ago −18.36%α −23.65% · $8.58
- T+60 · 4mo ago −21.98%α −25.05% · $8.20
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Arvinas (ARVN) announced FDA approval of VEPPANU (vepdegestrant), the first-ever PROTAC therapy, for ER+/HER2- ESR1-mutated advanced breast cancer after prior endocrine therapy. The approval came ahead of the PDUFA date and is based on the VERITAC-2 trial showing a 43% reduction in risk of disease progression or death vs fulvestrant (HR 0.57). This transformative milestone validates the PROTAC platform and provides a new treatment option for a significant unmet need, though commercial execution and competition remain risks.
Key Facts
- First FDA-approved PROTAC therapy (VEPPANU/vepdegestrant), approved ahead of June 5, 2026 PDUFA date
- Indication: ER+/HER2- ESR1-mutated advanced or metastatic breast cancer after ≥1 line of endocrine therapy
- VERITAC-2 Phase 3 trial (N=270 ESR1m) showed median PFS 5 months vs 2.1 months for fulvestrant (HR 0.57, p=0.0001)
- Discovered by Arvinas, jointly developed with Pfizer; companies plan to select a third-party partner for commercialization
- Arvinas and Pfizer share worldwide development costs, commercialization expenses, and profits
Financial Impact
Transformative for ARVN as first approved drug; no specific revenue guidance provided. Partnership with Pfizer limits upside but reduces risk. Commercial potential depends on market adoption and third-party collaboration.
Risk Factors
- Commercial execution risk; vepdegestrant may face competition from existing endocrine therapies and CDK4/6 inhibitors
- Safety signals including QTc prolongation, liver enzyme elevations, and cytopenias could limit uptake
- Dependence on Pfizer partnership and third-party selection for commercialization
- Potential for slower-than-expected physician adoption or payer reimbursement challenges
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3286140 |
Track record
21 reports on ARVN
5 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +28.62% at T+60 after the Feb 23, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 3, 202613d ago S-3 Bearish 5/10 Entry $7.42 to $6.55 Now $6.77 +8.76% ▲ +11.73% +7.32% vs SPY
- Nov 3, 202613d ago 8-K Bearish 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 4/10 Entry $7.09 to $7.42 Now $6.77 −4.51% ▲ +4.65% +3.00% vs SPY
- Sep 4, 202610w ago 144 Neutral 3/10 Entry $9.08 to $8.76 Now $6.77 −25.44% ▼ −3.52% −3.06% vs SPY
- Jun 22, 202621w ago 8-K Neutral 3/10 Entry $8.14 to $8.05 Now $6.77 −16.83% ▼ −1.11% −1.06% vs SPY
- Jun 2, 202623w ago 8-K Bearish 6/10 Entry $7.70 to $7.74 Now $6.77 +12.08% ▼ −0.52% −0.12% vs SPY
- May 12, 202626w ago 8-K Mixed 6/10 No price data
- May 12, 202626w ago 8-K Bullish 7/10 Entry $9.57 to $9.87 Now $6.77 −29.26% ▲ +3.13% +2.56% vs SPY
- May 12, 202626w ago Press Release Bearish 8/10 Entry $9.57 to $9.87 Now $6.77 +29.26% ▼ −3.13% −2.56% vs SPY
- May 8, 202627w ago 144 Neutral 2/10 Entry $9.66 to $9.57 Now $6.77 −29.92% ▼ −0.93% −0.80% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers